Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Shortages likely as Sandoz’s Canadian plant woes continue

February 20, 2012
Manufacturing and Production FDA, Novartis, Sandoz

Ongoing compliance problems at a plant in Canada operated by Novartis’ generics subsidiary Sandoz look set to cause supply disruptions …

News

Alnylam cuts workforce by a third

January 23, 2012
Research and Development, Sales and Marketing Alnylam, Novartis, job cuts, rnai

Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …

News

Novartis’ Signifor recommended in Europe

January 20, 2012
Research and Development, Sales and Marketing CHMP, Cushing's disease, Novartis, Signifor

A European committee has recommended Novartis’ Signifor for the treatment of a rare, debilitating endocrine disorder. The European Committee for …

News
Gilenya image

EMA to review safety of MS drug Gilenya

January 20, 2012
Research and Development, Sales and Marketing CHMP, EMA, Novartis, gilenya

The European Medicines Agency has begun a review into the safety of Novartis’ multiple sclerosis drug Gilenya. This follows concerns …

News

Novartis starts late-stage biosimilar trials for Amgen drugs

January 19, 2012
Research and Development, Sales and Marketing Amgen, Neulasta, Neupogen, Novartis

Novartis has begun Phase III biosimilar trials to copycat two of Amgen’s neutropenia drugs. The studies, which are being undertaken …

News
Lucentis image

Lucentis approved in China

January 18, 2012
Sales and Marketing China, Galvus, Lucentis, Novartis, em, emerging markets

Novartis’ eye treatment Lucentis has gained approval in China, and the firm has also launched its diabetes drug Galvus in …

News
Novartis image

Novartis reverses plant closure decision

January 18, 2012
Manufacturing and Production, Research and Development, Sales and Marketing Basel, Diovan, Novartis, Nyon, closure, job cuts

Novartis has said it will not close down a plant in Switzerland that had been due for closure, and has …

News

NICE says yes to Tasigna for resistant disease

January 13, 2012
Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna

NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …

News

Novartis to cut 2,000 US jobs

January 13, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Diovan, Novartis, job cuts

Novartis will slash 1,960 jobs in the US as it prepares for life without its blockbuster medicine Diovan. The hypertension …

News
Novartis building

Novartis recalls products as GMP issues close OTC facility

January 9, 2012
Manufacturing and Production FDA, Novartis, OTC

Novartis has revealed that it is temporarily shutting down a manufacturing facility in Nebraska, US, and recalling four products as …

News
FDA picture

FDA to probe Gilenya patient death

December 21, 2011
Sales and Marketing FDA, Novartis, gilenya

The FDA is investigating Novartis’s new multiple sclerosis treatment Gilenya after a patient died within hours of taking the drug. …

News
Novartis picture

Novartis opens cell-based flu vaccine plant in US

December 15, 2011
Manufacturing and Production Novartis, celll-based, vaccines

Novartis has officially started production at a first-of-its kind cell-based manufacturing facility for influenza vaccines in North Carolina, US. The …

News
Novartis' facility in North Carolina

Novartis warned over standards at generics sites

December 9, 2011
Manufacturing and Production CGMP Failures, FDA compliance, Novartis, Sandoz

The FDA has warned Novartis that three North American production facilities operated by its generics subsidiary Sandoz are failing to …

News
Glivec picture

NICE recommends two Novartis cancer treatments

December 6, 2011
Sales and Marketing Glivec, Novartis, Sprycel, Tasigna

Two of Novartis’ cancer drugs have been recommended by NICE for the first line treatment of chronic myeloid leukaemia (CML) …

News
Gilenya picture

Discount fails to sway NICE on Gilenya

December 1, 2011
Sales and Marketing NICE, Novartis, gilenya

NICE has once again rejected Novartis’ multiple sclerosis pill Gilenya despite the firm offering a patient access scheme. In its …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025